UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (754) 754
science & technology (690) 690
life sciences & biomedicine (651) 651
male (516) 516
female (396) 396
animals (355) 355
dipeptides - therapeutic use (353) 353
dipeptides - adverse effects (348) 348
middle aged (296) 296
dipeptides - pharmacology (293) 293
adult (260) 260
biological and medical sciences (231) 231
dipeptides - administration & dosage (214) 214
adamantane - analogs & derivatives (211) 211
medical sciences (209) 209
aged (206) 206
diabetes mellitus, type 2 - drug therapy (173) 173
pharmacology & pharmacy (161) 161
rats (143) 143
treatment outcome (137) 137
double-blind method (134) 134
adamantane - therapeutic use (126) 126
abridged index medicus (125) 125
adamantane - adverse effects (124) 124
pharmacology. drug treatments (121) 121
mice (112) 112
saxagliptin (107) 107
dipeptidyl-peptidase iv inhibitors - therapeutic use (103) 103
type 2 diabetes (99) 99
endocrinology & metabolism (98) 98
dipeptidyl-peptidase iv inhibitors - adverse effects (91) 91
hypoglycemic agents - therapeutic use (88) 88
dose-response relationship, drug (86) 86
time factors (85) 85
analysis (81) 81
drug therapy, combination (78) 78
hypoglycemic agents - adverse effects (75) 75
diabetes (74) 74
aspartame - adverse effects (73) 73
dipeptides - metabolism (72) 72
enalapril (69) 69
care and treatment (68) 68
risk factors (66) 66
research (65) 65
dipeptides - pharmacokinetics (64) 64
hypertension - drug therapy (64) 64
drug therapy (61) 61
adamantane - administration & dosage (60) 60
dipeptides - chemistry (60) 60
disease models, animal (60) 60
peptides (59) 59
adolescent (57) 57
diabetes mellitus, type 2 - blood (55) 55
cardiovascular system & cardiology (53) 53
neurosciences (53) 53
neurosciences & neurology (53) 53
oncology (53) 53
general & internal medicine (52) 52
clinical trials (50) 50
lisinopril (49) 49
medicine & public health (49) 49
young adult (49) 49
health aspects (48) 48
hypoglycemic agents - administration & dosage (48) 48
administration, oral (47) 47
aged, 80 and over (47) 47
biochemistry & molecular biology (47) 47
medicine, general & internal (47) 47
clinical trials as topic (46) 46
cardiovascular system (44) 44
cell biology (44) 44
research article (44) 44
dosage and administration (43) 43
proteins (43) 43
blood glucose - drug effects (42) 42
blood glucose - metabolism (42) 42
blood pressure - drug effects (42) 42
dipeptides - blood (42) 42
medicine, research & experimental (42) 42
research & experimental medicine (42) 42
studies (42) 42
diabetes mellitus, type 2 - complications (41) 41
dipeptidyl-peptidase iv inhibitors - administration & dosage (41) 41
internal medicine (41) 41
cardiac & cardiovascular systems (39) 39
chemistry (39) 39
drug administration schedule (39) 39
glycated hemoglobin a - metabolism (39) 39
medicine (39) 39
neurology (39) 39
toxicology (39) 39
angiotensin-converting enzyme inhibitors (38) 38
cancer (37) 37
glucose (37) 37
metformin (37) 37
pharmacology/toxicology (37) 37
rats, wistar (37) 37
medical research (36) 36
metformin - administration & dosage (36) 36
mice, inbred c57bl (36) 36
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1006) 1006
Russian (22) 22
German (12) 12
Chinese (6) 6
French (6) 6
Japanese (5) 5
Danish (3) 3
Portuguese (3) 3
Italian (2) 2
Norwegian (2) 2
Spanish (2) 2
Swedish (2) 2
Czech (1) 1
Dutch (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Diabetes care, ISSN 0149-5992, 11/2015, Volume 38, Issue 11, pp. 2009 - 2017
Journal Article
Clinical therapeutics, ISSN 0149-2918, 2014, Volume 36, Issue 12, pp. 2072 - 2079
Internal Medicine | Medical Education | DPP-IV inhibition | cardiovascular disease | heart failure | type 2 diabetes | Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) | Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD) | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Cardiology. Vascular system | Heart | Diabetes. Impaired glucose tolerance | Pharmacology. Drug treatments | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Heart failure, cardiogenic pulmonary edema, cardiac enlargement | Coronary heart disease | Endocrine pancreas. Apud cells (diseases) | Dipeptides - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptides - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrrolidines - adverse effects | Uracil - therapeutic use | Hospitalization | Pyrrolidines - therapeutic use | Uracil - adverse effects | Piperidines - therapeutic use | Piperidines - adverse effects | Adamantane - therapeutic use | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Heart Failure - chemically induced | Adamantane - adverse effects | Adamantane - analogs & derivatives | Nitriles - therapeutic use | Sitagliptin Phosphate - adverse effects | Uracil - analogs & derivatives | Heart failure | Regulatory agencies | Heart attacks | Peptides | Mortality | Cardiovascular disease | FDA approval | Patients | Studies | Databases | Diabetes | Drug therapy | Acute coronary syndromes | Index Medicus
Journal Article
Contemporary clinical trials, ISSN 1551-7144, 2011, Volume 32, Issue 3, pp. 324 - 332
Hematology, Oncology and Palliative Medicine | Cardiovascular | Saxagliptin and liraglutide | Sitagliptin | Alogliptin | Vildagliptin | Insulin inhalation powder | Exenatide | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Diabetes. Impaired glucose tolerance | General and cellular metabolism. Vitamins | Pharmacology. Drug treatments | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Triazoles - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | United States | Humans | Pyrrolidines - adverse effects | Allylamine - adverse effects | Randomized Controlled Trials as Topic - standards | Time Factors | Investigational New Drug Application - legislation & jurisprudence | Sitagliptin Phosphate | Incretins - chemistry | Colesevelam Hydrochloride | Incretins - physiology | United States Food and Drug Administration | Adamantane - adverse effects | Adamantane - analogs & derivatives | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Dipeptides - adverse effects | Allylamine - analogs & derivatives | Uracil - adverse effects | Piperidines - adverse effects | Pyrazines - adverse effects | Cardiovascular Diseases - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Liraglutide | Peptides - adverse effects | Practice Guidelines as Topic | Uracil - analogs & derivatives | Type 2 diabetes | Hypoglycemic agents | Drug therapy | Cardiovascular diseases | Drug approval | Risk factors | Diabetes therapy | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1317 - 1326
no | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Endocrine practice, ISSN 1530-891X, 11/2013, Volume 19, Issue 6, pp. 1025 - 1034
Journal Article
Journal Article